Cardiff Oncology, Inc. (CRDF)
Estimates & Forecasts•Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
Popular:
CRDF Price Targets Summary| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income | $-41M | $-45M | $-46M |
| EPS (Diluted) | $-0.93 | $-0.95 | $-0.69 |
| YoY Growth | — | — | — |
| Net Margin | -8492.0% | -6651.7% | -7732.0% |
USD · CRDF · Proprietary Model| Metric | 2025A | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|
| Revenue | $593,000 | $468,114 | $471,759 | $546,396 | $574,790 |
| Net Income | $-46M | $-10M | $-11M | $-273,198 | $-287,395 |
| EPS (Diluted) | $-0.69 | $-0.14 | $-0.13 | $-0.00 | $-0.00 |
| Free Cash Flow | $-38M | $-140,434 | $-141,527 | $-163,918 | $-172,437 |
Treat point estimates cautiously; use wider scenario ranges and position sizing discipline.
Quick answers to the most common questions about buying CRDF stock.
Cardiff Oncology, Inc.'s projected EPS for the next fiscal year is $-0.14. This estimate blends our quantitative model with Wall Street analyst consensus and carries a confidence score of 30/100. The model factors in revenue trajectory, margin path, and share buyback trends to arrive at this figure.
Our scenario-based model produces three price targets for Cardiff Oncology, Inc.: Bear case $N/A, Base case $N/A, and Bull case $N/A. These targets are derived by applying the median historical P/E ratio to forward EPS estimates under each growth scenario. They are not buy/sell recommendations.
Cardiff Oncology, Inc.'s projected revenue growth for the next fiscal year is -10.8%, reaching approximately $0.0B in total revenue. Growth estimates are probability-weighted and blend analyst consensus with our CAGR extrapolation model. Outer years (FY+3, FY+4) fade toward industry median growth rates.
Accuracy depends on several measurable factors. Our model confidence score of 30/100 is computed from revenue predictability (25% weight), margin stability (20%), historical earnings beat rate (20%), data depth (15%), analyst coverage (10%), and model-consensus agreement (10%). Currently expanding margins support higher forecast reliability. No forecast model is perfect — always cross-reference with your own analysis.
Cardiff Oncology, Inc.'s forward operating margin is estimated at -50.0% for the next fiscal year. The margin trend is currently "expanding". Our model tracks margin mean-reversion patterns and adjusts for sector-specific cost dynamics. Operating leverage is a key driver of EPS growth beyond top-line revenue expansion.
The v2 model uses a multi-step process: (1) Revenue is projected via blended CAGR with probability weighting, (2) Operating and net margins follow a mean-reversion path calibrated to sector norms, (3) EPS is derived from net income divided by projected diluted shares (accounting for buyback trends), (4) For FY+1 and FY+2, estimates are blended with analyst consensus based on coverage depth, (5) Price targets apply median historical P/E to forward EPS under bear/base/bull growth scenarios. All inputs are from public filings and third-party data providers.
The bear case ($N/A) assumes P25 revenue growth, worst-case margins, and multiple compression. Key risks include: unexpected margin contraction, revenue deceleration below model floor, regulatory headwinds, macro deterioration, or competitive disruption. A confidence score below 60 suggests higher estimate volatility. Always size positions according to the full scenario range, not just the base case.
Our model is above Wall Street consensus with a 79.6% gap. For FY+1, analyst estimates blend with our model at 20% analyst weight. By FY+3 and FY+4, estimates are purely model-driven as analyst coverage thins out at longer horizons.